Theo dõi
Luigi Portella
Luigi Portella
Istituto Nazionale Tumori di Napoli IRCCS G. Pascale
Email được xác minh tại istitutotumori.na.it
Tiêu đề
Trích dẫn bởi
Trích dẫn bởi
Năm
Androgen receptor splice variants determine taxane sensitivity in prostate cancer
M Thadani-Mulero, L Portella, S Sun, M Sung, A Matov, RL Vessella, ...
Cancer research 74 (8), 2270-2282, 2014
2792014
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in …
ST Tagawa, ES Antonarakis, A Gjyrezi, G Galletti, S Kim, D Worroll, ...
Clinical Cancer Research 25 (6), 1880-1888, 2019
1222019
Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer
C D'alterio, C Consales, M Polimeno, R Franco, L Cindolo, L Portella, ...
Current cancer drug targets 10 (7), 772-781, 2010
1102010
Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases
L Portella, R Vitale, S De Luca, C D’Alterio, C Ierano, M Napolitano, ...
PloS one 8 (9), e74548, 2013
982013
Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naive …
ES Antonarakis, ST Tagawa, G Galletti, D Worroll, K Ballman, ...
Journal of Clinical Oncology 35 (28), 3181-3188, 2017
952017
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
C D’Alterio, M Buoncervello, C Ieranò, M Napolitano, L Portella, G Rea, ...
Journal of Experimental & Clinical Cancer Research 38, 1-13, 2019
922019
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential
G Galletti, L Portella, ST Tagawa, BJ Kirby, P Giannakakou, DM Nanus
Molecular diagnosis & therapy 18, 389-402, 2014
792014
Differential role of CD133 and CXCR4 in renal cell carcinoma
C D’Alterio, L Cindolo, L Portella, M Polimeno, C Consales, A Riccio, ...
Cell Cycle 9 (22), 4492-4500, 2010
772010
Regulatory T cells, interleukin (IL)‐6, IL‐8, V ascular endothelial growth factor (VEGF), CXC L10, CXC L11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as …
M Polimeno, M Napolitano, S Costantini, L Portella, A Esposito, F Capone, ...
BJU international 112 (5), 686-696, 2013
762013
Ionizing radiation effects on the tumor microenvironment
L Portella, S Scala
Seminars in Oncology 46 (3), 254-260, 2019
702019
Inhibition of stromal CXCR4 impairs development of lung metastases
C D’Alterio, A Barbieri, L Portella, G Palma, M Polimeno, A Riccio, ...
Cancer Immunology, Immunotherapy 61, 1713-1720, 2012
702012
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
M Neve Polimeno, C Ierano, C D'alterio, N Simona Losito, M Napolitano, ...
Cellular & molecular immunology 12 (4), 474-482, 2015
582015
CXCL12 signaling in the tumor microenvironment
L Portella, AM Bello, S Scala
Tumor Microenvironment: The Role of Chemokines–Part B, 51-70, 2021
522021
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
C Ieranò, D Righelli, C D'Alterio, M Napolitano, L Portella, G Rea, ...
Journal for immunotherapy of cancer 10 (3), e004032, 2022
422022
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer
C D'Alterio, L Portella, A Ottaiano, M Rizzo, G Carteni, S Pignata, ...
Current Cancer Drug Targets 12 (6), 693-702, 2012
382012
Exploring the N-terminal region of CXC motif chemokine 12 (CXCL12): identification of plasma-stable cyclic peptides as novel, potent CXC chemokine receptor type 4 (CXCR4 …
S Di Maro, AM Trotta, D Brancaccio, FS Di Leva, V La Pietra, C Ierano, ...
Journal of Medicinal Chemistry 59 (18), 8369-8380, 2016
372016
Structure–activity relationships and biological characterization of a novel, potent, and serum stable CXC chemokine receptor type 4 (CXCR4) antagonist
S Di Maro, FS Di Leva, AM Trotta, D Brancaccio, L Portella, M Aurilio, ...
Journal of Medicinal Chemistry 60 (23), 9641-9652, 2017
332017
Ligand-based NMR study of CXC chemokine receptor type 4 (CXCR4)–ligand interactions on living cancer cells
D Brancaccio, D Diana, S Di Maro, FS Di Leva, S Tomassi, R Fattorusso, ...
Journal of Medicinal Chemistry 61 (7), 2910-2923, 2018
272018
CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells
C Ieranò, C D’Alterio, S Giarra, M Napolitano, G Rea, L Portella, ...
Cell death & disease 10 (8), 562, 2019
232019
CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis
C Ieranò, L Portella, S Lusa, G Salzano, C D'Alterio, M Napolitano, ...
Nanoscale 8 (14), 7562-7571, 2016
232016
Hệ thống không thể thực hiện thao tác ngay bây giờ. Hãy thử lại sau.
Bài viết 1–20